Cost effectiveness of an intensive blood glucose control policy in patients with type 2 diabetes: economic analysis alongside randomised controlled trial (UKPDS 41)
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To estimate the cost effectiveness of conventional versus intensive blood glucose control in patients with type 2 diabetes. DESIGN: Incremental cost effectiveness analysis alongside randomised controlled trial. SETTING: 23 UK hospital clinic based study centres. PARTICIPANTS: 3867 patients with newly diagnosed type 2 diabetes (mean age 53 years). INTERVENTIONS: Conventional (primarily diet) glucose control policy versus intensive control policy with a sulphonylurea or insulin. MAIN OUTCOME MEASURES: Incremental cost per event-free year gained within the trial period. RESULTS: Intensive glucose control increased trial treatment costs by pound 695 (95% confidence interval pound 555 to pound 836) per patient but reduced the cost of complications by pound 957 (pound 233 to pound 1681) compared with conventional management. If standard practice visit patterns were assumed rather than trial conditions, the incremental cost of intensive management was pound 478 (-pound 275 to pound 1232) per patient. The within trial event-free time gained in the intensive group was 0.60 (0.12 to 1.10) years and the lifetime gain 1.14 (0.69 to 1.61) years. The incremental cost per event-free year gained was pound 1166 (costs and effects discounted at 6% a year) and pound 563 (costs discounted at 6% a year and effects not discounted). CONCLUSIONS: Intensive blood glucose control in patients with type 2 diabetes significantly increased treatment costs but substantially reduced the cost of complications and increased the time free of complications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
Gupta, A., & Uribarri, J. (2016) · Hormone Research in Paediatrics · doi:10.1159/000444053 · Cited by 4,006
Costs, effects and C/E‐ratios alongside a clinical trial
Van Hout, B. A., Al, M. J., Gordon, G. S., & Rutten, F. F. H. (1994) · Health Economics · doi:10.1002/hec.4730030505 · Cited by 964
Eastman, R. C., Javitt, J. C., Herman, W. H., Dasbach, E. J., Copley-Merriman, C., Maier, W., Dong, F., Manninen, D., Zbrozek, A. S., Kotsanos, J., et al. (1997) · Diabetes Care · doi:10.2337/diacare.20.5.735 · Cited by 333
ESTIMATING CONFIDENCE INTERVALS FOR COST-EFFECTIVENESS RATIOS: AN EXAMPLE FROM A RANDOMIZED TRIAL
CHAUDHARY, M. A., & STEARNS, S. C. (1996) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(19960715)15:13<1447::aid-sim267>3.0.co;2-v · Cited by 313
Model of Complications of NIDDM: I. Model construction and assumptions
Eastman, R. C., Javitt, J. C., Herman, W. H., Dasbach, E. J., Zbrozek, A. S., Dong, F., Manninen, D., Garfield, S. A., Copley-Merriman, C., Maier, W., et al. (1997) · Diabetes Care · doi:10.2337/diacare.20.5.725 · Cited by 258
Confidence intervals for cost-effectiveness ratios: An application of Fieller's theorem
Willan, A. R., & OʼBrien, B. J. (1996) · Health Economics · doi:10.1002/(sici)1099-1050(199607)5:4<297::aid-hec216>3.0.co;2-t · Cited by 218
Screening for Treatable Diabetic Retinopathy: a Comparison of Different Methods
Buxton, M. J., Sculpher, M. J., Ferguson, B. A., Humphreys, J. E., Altman, J. F. B., Spiegelhalter, D. J., Kirby, A. J., Jacob, J. S., Bacon, H., Dudbridge, S. B., et al. (1991) · Diabetic Medicine · doi:10.1111/j.1464-5491.1991.tb01612.x · Cited by 164
Cited by
Representing uncertainty: the role of cost‐effectiveness acceptability curves
Fenwick, E., Claxton, K., & Sculpher, M. (2001) · Health Economics · doi:10.1002/hec.635 · Cited by 1,110
The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56)
STEVENS, R. J., KOTHARI, V., ADLER, A. I., & STRATTON, I. M. (2001) · Clinical Science · doi:10.1042/cs20000335 · Cited by 1,084
Cost‐effectiveness acceptability curves – facts, fallacies and frequently asked questions
Fenwick, E., O'Brien, B. J., & Briggs, A. (2004) · Health Economics · doi:10.1002/hec.903 · Cited by 943
Castaneda, C., Layne, J. E., Munoz-Orians, L., Gordon, P. L., Walsmith, J., Foldvari, M., Roubenoff, R., Tucker, K. L., & Nelson, M. E. (2002) · Diabetes Care · doi:10.2337/diacare.25.12.2335 · Cited by 844
Rubino, F., & Marescaux, J. (2004) · Annals of Surgery · doi:10.1097/01.sla.0000102989.54824.fc · Cited by 617
Clarke, P. M., Gray, A. M., Briggs, A., Farmer, A. J., Fenn, P., Stevens, R. J., Matthews, D. R., Stratton, I. M., Holman, R. R., & on behalf of the UK Prospective Diabetes Study (UKPDS) Group (2004) · Diabetologia · doi:10.1007/s00125-004-1527-z · Cited by 615
Self-citationFrequency of Severe Hypoglycemia Requiring Emergency Treatment in Type 1 and Type 2 Diabetes
Leese, G. P., Wang, J., Broomhall, J., Kelly, P., Marsden, A., Morrison, W., Frier, B. M., Morris, A. D., & For the DARTS/MEMO Collaboration (2003) · Diabetes Care · doi:10.2337/diacare.26.4.1176 · Cited by 559
“CONCLUSIONS — Achieving good glycemic control to minimize the risk of diabetic microvascular complications in type 1 and type 2 diabetes (5,6,9,19) is reputed to be cost effective in that the increased treatment costs are offset by reduced cost of treating complications and improved quality of life (20).”
BackgroundThe CDC Diabetes Cost-effectiveness Group (2002) · JAMA · doi:10.1001/jama.287.19.2542 · Cited by 508
Cost-Effectiveness of Interventions to Prevent and Control Diabetes Mellitus: A Systematic Review
Li, R., Zhang, P., Barker, L. E., Chowdhury, F. M., & Zhang, X. (2010) · Diabetes Care · doi:10.2337/dc10-0843 · Cited by 491
Generalisability in economic evaluation studies in healthcare: a review and case studies
Sculpher, M., Pang, F., Manca, A., Drummond, M., Golder, S., Urdahl, H., Davies, L., & Eastwood, A. (2004) · Health Technology Assessment · doi:10.3310/hta8490 · Cited by 441
Is diabetic retinopathy an inflammatory disease?
Adamis, A. P. (2002) · British Journal of Ophthalmology · doi:10.1136/bjo.86.4.363 · Cited by 341
Patient navigators for people with chronic disease: A systematic review
McBrien, K. A., Ivers, N., Barnieh, L., Bailey, J. J., Lorenzetti, D. L., Nicholas, D., Tonelli, M., Hemmelgarn, B., Lewanczuk, R., Edwards, A., et al. (2018) · PLOS ONE · doi:10.1371/journal.pone.0191980 · Cited by 307
Fenwick, E., Marshall, D. A., Levy, A. R., & Nichol, G. (2006) · BMC Health Services Research · doi:10.1186/1472-6963-6-52 · Cited by 279
The burden of type 2 diabetes: are we doing enough?
Zimmet, P. (2003) · Diabetes & Metabolism · doi:10.1016/s1262-3636(03)72783-9 · Cited by 260
The TODAY Study Group (2007) · Pediatric Diabetes · doi:10.1111/j.1399-5448.2007.00237.x · Cited by 260
Lifetime Costs of Complications Resulting From Type 2 Diabetes in the U.S.
Caro, J. J., Ward, A. J., & O’Brien, J. A. (2002) · Diabetes Care · doi:10.2337/diacare.25.3.476 · Cited by 258
Gerich, J. E. (2003) · Mayo Clinic Proceedings · doi:10.4065/78.4.447 · Cited by 222
Rodríguez-Gutiérrez, R., & Montori, V. M. (2016) · Circulation: Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.116.002901 · Cited by 176
Clarke, P. M., Gray, A. M., Briggs, A., Stevens, R. J., Matthews, D. R., Holman, R. R., & (UKPDS), O. B. O. T. U. P. D. S. (2005) · Diabetologia · doi:10.1007/s00125-005-1717-3 · Cited by 155
“However, such comparisons are restricted by the fact that the results reported to date from the UKPDS have only measured outcomes in terms of life years gained [4, 6] or endpoint-free time [2].”
BackgroundMethodSelf-citationPalmer, A. J., Roze, S., Valentine, W. J., Spinas, G. A., Shaw, J. E., & Zimmet, P. Z. (2004) · Clinical Therapeutics · doi:10.1016/s0149-2918(04)90029-x · Cited by 128
Intensive Integrated Therapy of Type 2 Diabetes
Gæde, P., & Pedersen, O. (2004) · Diabetes · doi:10.2337/diabetes.53.suppl_3.s39 · Cited by 108
Dijkstra, R. F., Niessen, L. W., Braspenning, J. C. C., Adang, E., & Grol, R. T. P. M. (2006) · Diabetic Medicine · doi:10.1111/j.1464-5491.2005.01751.x · Cited by 81
Igarashi, A., Maruyama-Sakurai, K., Kubota, A., Akiyama, H., Yajima, T., Kohsaka, S., & Miyata, H. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01270-8 · Cited by 17
Metadata
- Authors
- Gray, A.
- Venue
- BMJ
- Publisher
- BMJ
- Published
- 2000-05-20
- Volume
- 320
- Issue
- 7246
- Pages
- 1373-1378
- ISSN
- 0959-8138 (ISSN-L)
- OpenAlex
- W1976787772
- Cited by
- 323
- References
- 12
- FWCI
- 73.85
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.